Diagnosis

Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, X-ray, LTD, Cardiology, Patient, Science, Radiology, SCL, Department of Tourism (Philippines), NANO, Teleradiology, ARC, Marketing, Medical device

PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories).

Key Points: 
  • Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.
  • The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, tomographic images.
  • The collaboration will also include SCL Science integrating Nanox’s AI solutions in remote image analysis and other operations.
  • “We are excited to work with AhealthZ and SCL Science to bring our comprehensive medical imaging solutions to South Korea, a country of over 51 million people and one of the world’s most advanced technological markets,” said Erez Meltzer, Nanox Chief Executive Officer.

Emerging Markets Report: Follow the Leader

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Disease, Biomedical Research, Patient, HPC, Health care, Artificial intelligence, NVDA, AI, WELL, A.I, TSX, Inflammatory bowel disease, Love, NVIDIA, Map, AIDX, Medicine, Medical device

ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- For some time now the market has been in love with Nvidia (NVDA), the behemoth stock which has been to say the least, a bell cow for the market. And while we don’t discuss actual share prices in our pages, preferring to focus instead on the items that historically drive favorable valuations, Nvidia’s price appreciation has been remarkable and is, powered by their revenue growth and the public’s attraction to Artificial Intelligence technology.

Key Points: 
  • And we believe that the intersection of Health Care and Artificial Intelligence is the first half of that formula.
  • With NVIDIA, healthcare institutions can harness the power of AI and high-performance computing (HPC) to define the future of medicine.
  • If the revenue trend continues, analysts, partners, and market interests may follow.
  • And HEALWELL is certainly following the leader, acquiring and developing potentially lucrative Healthcare A.I.

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, NIHCC, FLA, NIH, Male, Urinary incontinence, Erectile dysfunction, CLS, Bangladesh Technical Education Board, Medical imaging

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.

Key Points: 
  • LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • “This second order of our TRANBERG Focal Laser Ablation accessories enables our continued collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories.

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Biopsy, Fatty liver disease, Cirrhosis, Exercise, F2, Patient, Prescription, MD, Diet, Fibrosis, Pharmacy, NASH, Therapy, FDA, THR, JD

I can finally tell my appropriate patients with moderate to advanced fibrosis that we have an approved treatment to help improve fibrosis and resolve NASH.

Key Points: 
  • I can finally tell my appropriate patients with moderate to advanced fibrosis that we have an approved treatment to help improve fibrosis and resolve NASH.
  • Madrigal is committed to helping appropriate patients who may benefit from Rezdiffra access the medication through the Madrigal Patient Support program.
  • This program is designed to help patients navigate insurance and affordability challenges and provide co-pay support for eligible patients.
  • Madrigal has also established a patient assistance program (PAP) to help patients with no insurance access Rezdiffra.

Creyos Health Announces Addition of Dementia Screening, Testing, and Care Planning to its Online Platform

Retrieved on: 
Tuesday, April 9, 2024
Western University, Diagnosis, AMGA, Research, Dementia, Prevalence, Entrepreneurship, Deficit spending, Disease, Caregiver, Patient, American Medical Group Association, OBE, Doctor of Philosophy, Statistics, MCI, Cognition

This protocol, now available in the Creyos platform, is the result of 30 years of rigorous research and scientific validation.

Key Points: 
  • This protocol, now available in the Creyos platform, is the result of 30 years of rigorous research and scientific validation.
  • It offers full spectrum cognitive care, from early detection of mild cognitive impairment, to testing for an accurate dementia diagnosis, followed by tailored care planning, and ongoing longitudinal monitoring.
  • Dementia testing includes four additional tasks and behavioral health questionnaires, aligned with DSM-5 diagnostic criteria for dementia.
  • “We started Creyos because we noticed a significant gap in how cognitive health was being addressed,” said Marc Lipton, Co-Founder and CEO of Creyos.

ASDS/A Board of Directors Appoints Tara Azzano as Executive Director

Retrieved on: 
Monday, April 8, 2024
Research, Diagnosis, Executive, Patient, Association management, FRCPC, Society, Interim, Meeting, ASDS, Medicine, Management

Schaumburg, IL, April 08, 2024 (GLOBE NEWSWIRE) -- Tara L. Azzano was recently named Executive Director of the American Society for Dermatologic Surgery (ASDS), the largest specialty organization in the U.S. exclusively representing dermatologic surgeons.

Key Points: 
  • Schaumburg, IL, April 08, 2024 (GLOBE NEWSWIRE) -- Tara L. Azzano was recently named Executive Director of the American Society for Dermatologic Surgery (ASDS), the largest specialty organization in the U.S. exclusively representing dermatologic surgeons.
  • She joined the organization in 2002 as the Director of Education, Research and Meetings.
  • Azzano has almost a quarter of a century’s worth of experience with ASDS/A, and her institutional knowledge of our Society is unprecedented.
  • “I am truly thrilled to have been chosen as the next Executive Director and to continue to share my passion for dermatologic surgery.

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Retrieved on: 
Monday, April 8, 2024
Diagnosis, The Lancet, Depression, NASW, Partnership, PAP, Psychotherapy, Palliative care, Patient, Research, Gold, American Psychological Association, Standard of care, Anxiety, Cancer, Doctor of Philosophy, Quality of life, Adjustment disorder, Social work, World Health Organization, Clinical trial, Safety, Adjustment, WHO, National Association, DSM-IV codes, APA, FDA, Physician, Health, PBM, Practitioner, Nursing

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.
  • According to Lancet Oncology, Adjustment Disorder affects as many as 19% of patients following a life-limiting cancer diagnosis.
  • “The success of the clinical trial relies on rigorous, standardized therapist training designed to achieve the highest standard of patient care,” said Elizabeth Nielson, PhD, Fluence co-founder.
  • Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Retrieved on: 
Sunday, April 7, 2024
Diagnosis, OS, Nephrectomy, Immunotherapy, DCR, Oncology, Risk, Patient, Shanda, Malignancy, Death, IMDC, Carcinoma, Renal cell carcinoma, Trial of the century, RCC, National Medical Products Administration, ESMO, HKEX, IRC, PFS, Annals of Oncology, Axitinib, Independent Review Committee, Pharmaceutical industry

Renal carcinoma is the third most common malignancy of the urinary system globally, and RCC accounts for 80%~90% of all cases of renal carcinoma.

Key Points: 
  • Renal carcinoma is the third most common malignancy of the urinary system globally, and RCC accounts for 80%~90% of all cases of renal carcinoma.
  • There were approximately 77,000 new cases of and 46,000 deaths due to renal carcinoma in China in 2022.
  • Distant metastasis occurred in about one-third of renal carcinoma patients at initial diagnosis, and in 20%-50% of localized patients after nephrectomy.
  • “The approval of toripalimab combined with axitinib addresses the gap in first-line immunotherapy for renal cancer in China.

Sutter Health Announces Significant Investment in a New Advanced Multi-Specialty Neurosciences Care Complex in San Francisco’s Mission Neighborhood

Retrieved on: 
Thursday, April 4, 2024
Neurology, Diagnosis, Brain, Cardiology, Partnership, Physician, Health, Patient, SAN, Stroke, Research, Aneurysm, Elective surgery, Sutter Health, General surgery, Forbes Norris, Neurosurgery, Investment, Pediatrics, Hospital, Endocrinology, Podiatry, Graduate medical education, Rehabilitation, Nursing

The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.

Key Points: 
  • The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.
  • Finally, Sutter will expand primary care and women’s care services on the Mission Bernal Campus at the Monteagle building ( 1580 Valencia St .).
  • "At Sutter Health, the commitment to expanding access to high-quality care is unstoppable,” said Ken McNeely, Sutter Health board chair.
  • “This investment underscores the organization's dedication to meeting the health care needs of Northern California communities, ensuring that patients receive exceptional care close to home.

BridgingApps® to Curate Apps for Sentara Health Plans Members with Special Health Care Needs

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Health, Smartphone, Database, Social, Caregiver, Patient, School, Hospital, Sentara Healthcare, Quality of life, Safety, Disability, Nursing

HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to provide expertly vetted lists of mobile device applications, or apps, to support its members who have special health care needs or disabilities.

Key Points: 
  • HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to provide expertly vetted lists of mobile device applications, or apps, to support its members who have special health care needs or disabilities.
  • Later this year, qualified Sentara Health Plans members will have access to a comprehensive list of curated apps recommended by BridgingApps Care Managers.
  • This will better equip members to manage their health decisions and develop important skill sets, ultimately improving their health and quality of life.
  • BridgingApps’ free App Search Tool, Search.BridgingApps.org , houses a database of apps trialed and reviewed by therapists, special education teachers, experts, and special needs users.